Anti-obesity Effects of Dandelion (Taraxacum Officinale L.)

Not Applicable

Completed

• Conditions: Obese Women; Perimenopause
• Interventions: Dietary Supplement: The dandelion extract; Drug: Xenical

• Registration Number: NCT06625736
• Lead Sponsor: October 6 University

Brief Summary

The study investigates the effectiveness of the natural product Dandelion in treating obesity in premenopausal women through a randomized interventional trial, measuring various parameters and biomarkers.

Detailed Description

The study aims to explore the anti-obesity effects of dandelion supplementation in premenopausal obese women. The research will measure changes in appetite, energy intake, body weight, composition, lipid profile, and inflammatory markers, providing evidence of dandelion\'s efficacy as an anti-obesity phototherapy. The randomized interventional trial will measure multiple parameters and biomarkers.

Study Timeline

• Study Start: 2024-01-05
• Status Verified: 2024-09
• Primary Completion: 2024-09-07
• Study Completion: 2024-09-07
• Study First Submitted: 2024-09-30
• Study First Submitted QC: 2024-10-01
• Last Update Submitted: 2024-10-01
• Study First Posted: 2024-10-03
• Last Update Posted: 2024-10-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 120

Inclusion Criteria

Premenopausal women with obesity. Age between 18-45 years Stable body weight in the past 3 months

Read More

Exclusion Criteria

Pregnancy Breastfeeding Diabetes Cardiovascular diseases kidney or liver diseases use of medications that affect body weight Smoking Allergy to dandelion or related plants

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
The dandelion extract group	The dandelion extract	The dandelion extract group: 60 patients will receive 500 mg capsules of dandelion leaf extract, given 3 times per day before meals and for 12 weeks.
Control group	Xenical	The Xenical group:60 patients will receive identical capsules of 120mg (one capsule) to be taken three times daily with meals and for 12 weeks, equaling 360mg total daily dose.

Primary Outcome Measures

Name	Time	Method
Changes in body weight	monthly change, assessed up to 3 months
Change in fat mass	Monthly change, assessed up to 3 months

Secondary Outcome Measures

Name	Time	Method
Appetite Ratings	monthly change, assessed up to 3 months
Dietary intake via 24-hour recalls	Recorded for patients daily, assessed up to 3 months
Lipid profile	Monthly change, assessed up to 3 months
CRP	Monthly change, assessed up to 3 months	C-reactive protein
TNF-α	Monthly change, assessed up to 3 months
IL-6	Monthly change, assessed up to 3 months	Interelukine 6
IL-16	Monthly change, assessed up to 3 months
Glycemic indices	Monthly change, assessed up to 3 months

Trial Locations

Locations (1)

October 6 University Hospital; 🇪🇬 Giza, Egypt